medigraphic.com
ISSN 1405-1710 (Impreso)

2025, Número 1

<< Anterior Siguiente >>

Rev Cent Dermatol Pascua 2025; 34 (1)


Revisión sistemática del uso de trifaroteno en acné: efectividad y efectos secundarios

Cruz-Gómez LG, Morales-Sánchez MA

Idioma: Español
Referencias bibliográficas: 26
Paginas: 16-24
Archivo PDF: 825.17 Kb.


RESUMEN

Los retinoides tópicos son ampliamente usados en dermatología. El trifaroteno es un retinoide de reciente introducción, el cual cuenta con muy pocos estudios para valorar su efectividad y tolerancia. Realizamos una revisión sistemática basados en la guía PRISMA y en la herramienta de detección de riesgo de sesgos RoB-2 para determinar la efectividad y tolerancia del trifaroteno en el tratamiento del acné. Comparado contra placebo, el trifaroteno cuenta con una mayor efectividad para el tratamiento del acné, disminuyendo la IGA basal a las 12 semanas, teniendo un riesgo relativo de 1.65 contra placebo. El trifaroteno tiene mayor efectividad en el tratamiento del acné comparado con el placebo, así como baja cantidad de eventos adversos asociados al tratamiento. Es necesario comparar la efectividad de trifaroteno contra los tratamientos de primera línea de acné para demostrar su superioridad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alomary SA, Pei M, Lipner SR. Retinoids and risk: a FAERS databasestudy of topical retinoids. J Cutan Med Surg. 2024; 28: 393-394

  2. Baldwin H, Webster G, Stein Gold L et al. 50 years of topical retinoidsfor acne: evolution of treatment. Am J Clin Dermatol. 2021; 22: 315-327. doi: 10.1007/s40257-021-00594-8.

  3. Motamedi M, Chehade A, Sanghera R, Grewal P. A Clinician’sguide to topical retinoids. J Cutan Med Surg. 2022; 26: 71-78. doi:10.1177/12034754211035091.

  4. Aubert J, Piwnica D, Bertino B et al. Nonclinical and humanpharmacology of the potent and selective topical retinoic acidreceptor-γ agonist trifarotene. Br J Dermatol. 2018; 179: 442-456.

  5. Reynolds RV, Yeung H, Cheng CE et al. Guidelines of care for themanagement of acne vulgaris. J Am Acad Dermatol. 2024; 90: 1006.e1-1006.e30. doi: 10.1016/j.jaad.2023.12.017.

  6. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol.2013; 168: 474-485. doi: 10.1111/bjd.12149.

  7. Tan J. Identifier NCT02566369, efficacy and safety of CD5789(trifarotene) 50 μg/g cream versus vehicle cream in Acne vulgaris.2019. Available in: https://clinicaltrials.gov/study/NCT02566369?term=NCT02566369&rank=1

  8. Tan J, Thiboutot D, Popp G et al. Randomized phase 3 evaluation oftrifarotene 50 μg/g cream treatment of moderate facial and truncalacne. J Am Acad Dermatol. 2019; 80: 1691-1699.

  9. Blume-Peytavi U, Fowler J, Kemény L et al. Long-term safety andefficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selectivetopical retinoid, in patients with moderate facial and truncal acne. J EurAcad Dermatol Venereol. 2020; 34: 166-173. doi: 10.1111/jdv.15794.

  10. Del Rosso JQ, Johnson SM, Schlesinger T et al. A randomized,controlled trial of trifarotene plus doxycycline for severe Acne vulgaris.J Clin Aesthet Dermatol. 2022; 15: E53-E59.

  11. Eichenfield L, Kwong P, Lee S, Krowchuk D, Arekapudi K, Hebert A.Advances in topical management of adolescent facial and truncal acne:a phase 3 pooled analysis of safety and efficacy of trifarotene 0.005%cream. J Drugs Dermatol. 2022; 21: 582-586. doi: 10.36849/JDD.6778.

  12. Lee WG, Koh YG, Shin SH, Park KY, Lee HW. Case series ofacanthosis nigricans treated with topical trifarotene cream. J CosmetDermatol. 2023; 22: 2862-2864. doi: 10.1111/jocd.15777.

  13. Schleicher S, Moore A, Rafal E et al. Trifarotene reduces risk for atrophicacne scars: results from a phase 4 controlled study. Dermatol Ther(Heidelb). 2023; 13: 3085-3096. doi: 10.1007/s13555-023-01042-7.

  14. Fabbrocini G, Cacciapuoti S, Monfrecola G. A qualitative investigationof the impact of acne on health-related quality of life (HRQL):development of a conceptual model. Dermatol Ther (Heidelb). 2018;8: 85-99. doi: 10.1007/s13555-018-0224-7.

  15. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, FinlayAY. The quality of life in acne: a comparison with general medicalconditions using generic questionnaires. Br J Dermatol. 1999; 140:672-676. doi: 10.1046/j.1365-2133.1999.02768.x.

  16. Alexis A, Del Rosso JQ, Forman S et al. Importance of treating acnesequelae in skin of color: 6-month phase IV study of trifarotene with anappropriate skincare routine including UV protection in acne-inducedpost-inflammatory hyperpigmentation. Int J Dermatol. 2024; 63: 806-815. doi: 10.1111/ijd.17189.

  17. Chan K. Identifier NCT02556788, double-blind efficacy and safety ofCD5789 (trifarotene) 50 μg/g cream versus vehicle cream in Acnevulgaris. 2019. Available in: https://clinicaltrials.gov/study/NCT02556788?term=NCT02556788&rank=1

  18. Graeber M. Identifier NCT01616654, dose range study of CD5789 inAcne vulgaris. 2021. Available in: https://clinicaltrials.gov/study/NCT01616654?term=NCT01616654&rank=1

  19. Gollnick HP, Draelos Z, Glenn MJ et al. Adapalene-benzoyl peroxide,a unique fixed-dose combination topical gel for the treatment ofacne vulgaris: a transatlantic, randomized, double-blind, controlledstudy in 1670 patients. Br J Dermatol. 2009; 161: 1180-1189. doi:10.1111/j.1365-2133.2009.09209.x.

  20. Eichenfield LF, Jarratt M, Schlessinger J et al. Adapalene 0.1%lotion in the treatment of acne vulgaris: results from two placebocontrolled,multicenter, randomized double-blind, clinical studies. JDrugs Dermatol. 2010; 9: 639-646.

  21. Tan J, Humphrey S, Vender R et al. A treatment for severe nodularacne: a randomized investigator-blinded, controlled, noninferiority trialcomparing fixed-dose adapalene/benzoyl peroxide plus doxycyclinevs. oral isotretinoin. Br J Dermatol. 2014; 171: 1508-1516. doi:10.1111/bjd.13191.

  22. Culp L, Moradi Tuchayi S, Alinia H, Feldman SR. Tolerability oftopical retinoids: are there clinically meaningful differences amongtopical retinoids? J Cutan Med Surg. 2015; 19: 530-538. doi:10.1177/1203475415591117.

  23. Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoidsin acne vulgaris: a systematic review. Am J Clin Dermatol. 2019; 20:345-365. doi: 10.1007/s40257-019-00423-z.

  24. Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoidtherapy. J Drugs Dermatol. 2004; 3: 641-651.

  25. Thielitz A, Gollnick H. Topical retinoids in Acne vulgaris: updateon efficacy and safety. Am J Clin Dermatol. 2008; 9: 369-381. doi:10.2165/0128071-200809060-00003.

  26. Stein Gold L, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate andsevere inflammatory acne vulgaris effectively treated with single-agenttherapy by a new fixed-dose combination adapalene 0.3%/benzoylperoxide 2.5% gel: a randomized, double-blind, parallel-group,controlled study. Am J Clin Dermatol. 2016; 17: 293-303. doi: 10.1007/s40257-016-0178-4.




2020     |     www.medigraphic.com